The HCPLive Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.
October 8th 2024
An interim analysis of the PRO-SPIRIT study compared outcomes at 3 months after starting new treatments for psoriatic arthritis.
Collaborating Across the Continuum™: The Role of Multidisciplinary Care in the Management of Patients with Exocrine Pancreatic Insufficiency
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
October 16, 2024
Register Now!
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
October 26, 2024
Register Now!
6th Annual Advanced Practice Collaborative
View More
SimulatED™: Personalizing Treatment Choices to Achieve Glycemic and Weight Management Goals
View More
Cases and Conversations™: Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis
November 18, 2024
Register Now!
Shaping the Management of COPD with Biologic Therapy
View More
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Expert Illustrations & Commentaries™: Exploring the Role of Novel Agents for the Management of IgA Nephropathy
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Clinical ShowCase™: Finding the Best Path Forward for Patients with COPD
View More
A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology
View More
Surv.AI Says™: What Clinicians and Patients Are Saying About Glucose Management in the Technology Age
View More
Clinical ShowCase™: Forming a Personalized Treatment Plan for a Patient With ANCA-Associated Vasculitis
View More
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
Patient, Provider & Caregiver Connection™: Implementing an Effective Management Plan to Improve Outcomes in IgA Nephropathy
View More
Spondyloarthritis Lesions Redefined by Physician Group
October 2nd 2019An international physician group writing in the British journal Annals of the Rheumatic Diseases, has updated recommended parameters that constitute lesions in the sacroiliac joints of patients with spondyloarthritis. The definitions of capsulitis, enthesitis, fat lesion and erosion were revised and new definitions were developed for joint space enhancement, joint space fluid, fat metaplasia in an erosion cavity, ankylosis and bone bud.
Alcohol Consumption Linked to Spinal Structural Progression in Axial Spondyloarthritis
October 2nd 2019Previously, smoking was the sole known modifiable predictor of spinal structural damage, but now alcohol consumption has been shown to be associated with the progression of spinal structural damage in axial spondyloarthritis―specifically by increasing the odds of syndesmophyte progression over two years.
How Best to Assess Spondyloarthritis Lesions
October 2nd 2019In this slideshow, we highlight 12 recommendations for assessing MRI lesions on the sacroiliac joints of patients with spondyloarthritis. The recommendations were made by the Assessment of Spondyloarthritis International Society (ASAS) MRI working group and published in the British journal Annals of the Rheumatic Diseases earlier this year.
Study Finds Increased Infusion Reactions With Infliximab Versus Golimumab
October 1st 2019Sheetal Desai, MD, AWARE investigator and assistant clinical professor of medicine at UC Irvine, discusses full 52-week results of study comparing 2 popular rheumatoid arthritis patients and what the observed safety profile means from a patient-centered perspective.
Retinopathy Risk in Lupus Increases With Longer Hydroxychloroquine Use
October 1st 2019The incidence of retinopathy among systemic lupus erythematosus (SLE) patents treated with hydroxychloroquine increased with longer treatment duration, but could be predicted by monitoring blood levels of the drug, say researchers writing in Arthritis & Rheumatology this month.
FDA Approves New Treatment for Rare Pediatric Vasculitis
October 1st 2019The U.S. Food and Drug Administration has approved rituximab (Rituxan, Genentech) for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children 2 years of age and older in combination with glucocorticoids.
52-Week AWARE Results Show Efficacy, Safety of Rheumatoid Arthritis Therapies
September 30th 2019Aaron Broadwell, MD, rheumatologist and AWARE investigator, discusses his interpretation of the full 52-week results of the trial, which examined golimumab and infliximab in patients with rheumatoid arthritis in a real-world setting.
Tofacitinib Improves Quality of Life, Skin Symptoms In Psoriatic Arthritis
September 30th 2019A post hoc analysis of the OPAL Beyond and OPAL Broaden studies found tofacitinib improved skin-related symptoms and health-related quality of life in psoriatic arthritis patients with an inadequate response to csDMARDs or TNFi treatment.
Theresa Lawrence Ford, MD: State of Burnout in Rheumatology
September 28th 2019Theresa Lawrence Ford, MD, CEO and medical director of North Georgia Rheumatology Group and board member of the Association of Women in Rheumatology, gives her opinion on the current state of burnout among rheumatologists.
Maria Greenwald, MD: Physician Knowledge of Prescription Cost Burden
September 27th 2019Maria Greenwald, MD, rheumatologist, discusses what she sees as a glaring issue in medicine—the lack of knowledge among many physicians as to how much treatments will cost and how to mitigate the impact of those costs.
Maria Greenwald, MD: How to Help Patients Save on Prescription Costs
September 27th 2019Maria Greenwald, MD, rheumatologist with Desert Medical Advances, discusses the results of a study she conducted that sought to identify the most effective ways a physician can advise a patient on how to save money on treatments.
ACR Rheumatic Disease Report Card: How Well Is Your State Doing?
September 27th 2019As we say goodbye to September and Rheumatic Disease Awareness Month, we'd like to take a quick look at access to care for patients with rheumatic disease. In this slideshow, we highlight the best and worst performers (spoiler alert: only one state received an A.)
Janet Pope, MD: Rheumatoid Areas in Most Need of Research
September 27th 2019While conferences and annual meetings are often the place clinicians are exposed to new data, there are often niche areas where they seek further guidance or information. Janet Pope, MD, discusses where she would like to see more research dedicated.
Janet Pope, MD: Need For Cost-Effective Treatments in Rheumatology
September 26th 2019Janet Pope, MD, professor of medicine at the University of Toronto, discusses whether she believes clinicians will ever transition away from DMARDs and biologics due to the high cost and what the alternatives are for those patients.